12:00 AM
 | 
May 07, 2012
 |  BC Week In Review  |  Company News  |  Other News

Biogen Idec, Royalty Pharma autoimmune news

Royalty Pharma paid former shareholders of Fumapharm AG $761 million in cash to acquire a portion of earn-out rights related to multiple sclerosis product BG-12 and psoriasis drug...

Read the full 138 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >